All In Biotech

Drug Trial Radar · NCT07927816

CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

A Single-Arm, Dose-Escalation Clinical Study on the Safety of CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Aug 31, 2028

Study completion Aug 31, 2029

Sponsor

Lead sponsor
Liping DouAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hebei Senlang Biotechnology Inc., Ltd.
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, single-arm, prospective, investigator-initiated dose-escalation study to evaluate the safety, tolerability, preliminary efficacy, and cellular kinetics of an in vivo CAR-T cell immunotherapy targeting CD19 sequentially followed by CD22, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). The investigational product is a targeted lentiviral vector that transduces the patient's endogenous T/NK cells in situ; no leukapheresis, ex vivo manufacturing, or lymphodepleting conditioning is required. Participants receive an intravenous infusion of CD19-targeted in vivo CAR-T on Day 0, followed by an intravenous infusion of CD22-targeted in vivo CAR-T on Day 7. Before the Day 7 infusion, the investigator will assess each participant to determine whether the second infusion should proceed, based on: (i) the proportion of CAR-positive T/NK cells in peripheral blood, which reflects the success of in vivo transduction and early expansion after the first infusion; (ii) the maximum grade and current control of adverse events occurring after the first infusion, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS); and (iii) the participant's general condition, including Eastern Cooperative Oncology Group (ECOG) performance status and vital organ function (cardiac, hepatic, renal, pulmonary, and coagulation). The second infusion will be postponed or cancelled if any of these assessments indicates that the risk outweighs the benefit, for example grade \>=3 CRS or grade \>=2 ICANS that has not resolved to grade \<=1, or investigator-judged deterioration in organ function. Dose escalation follows a traditional 3+3 design with planned dose levels of 1×10\^9, 3×10\^9, and 6×10\^9 transducing units (TU), guided by dose-limiting toxicities (DLTs) assessed during Days 0-28; higher dose levels may be explored if the maximum tolerated dose is not reached. Treatment-emergent adverse events and serious adverse events, including CRS, immune effector cell-associated neurotoxicity syndrome (ICANS), hematologic toxicity, and organ toxicity, will be assessed. Preliminary antitumor activity will be evaluated by objective response rate (ORR), overall survival (OS), and progression-free survival (PFS), and the expansion and persistence of in vivo-generated CAR-T cells in peripheral blood will also be evaluated.

Conditions

  • Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
  • In Vivo CAR-T
  • B-Cell Acute Lymphoblastic Leukemia

Interventions

  • CD19-Targeted In Vivo CAR-T Injection (first infusion, Day 0); CD22 -Targeted In Vivo CAR-T Injection (second infusion, Day 7)Drug

    The investigational products are engineered lentiviral vector-based in vivo gene therapy products. The viral envelope receptor-binding domain has been mutated to abolish native pantropic infectivity, and a targeting module composed of an anti-CD7 nanobody (VHH) and a T/NK-cell-specific ligand (CD58 extracellular domain) has been incorporated into the envelope, enabling specific transduction of circulating T cells and NK cells in situ and expression of a chimeric antigen receptor directed against CD19 (first infusion, Day 0) or CD22 (second infusion, Day 7). No leukapheresis, ex vivo manufacturing, or lymphodepleting conditioning is required. Dose escalation follows a traditional 3+3 design with planned dose levels of 1×10\^9, 3×10\^9, and 6×10\^9 transducing units (TU), guided by the occurrence of dose-limiting toxicities (DLTs).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: From the first in vivo CAR-T infusion through 12 months after treatment
  2. Adverse EventsTime frame: From the first in vivo CAR-T infusion through 12 months after treatment
  3. Cytokine Release SyndromeTime frame: From the first in vivo CAR-T infusion through 12 months after treatment
  4. Immune Effector Cell-associated Neurotoxicity SyndromeTime frame: From the first in vivo CAR-T infusion through 12 months after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.